Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available?
Description
With knowledge of covid-19 less than a year old, treatment remains fraught with uncertainty. Preprint data and adaptive clinical trials are imperfect but can guide active decision making in life-or-death situations, says Raymond M Johnson. But Peter Doshi and David Healy argue that doctors and professional societies should state that, without complete data transparency, they will not endorse covid-19 products as being based on science.Keyword
Coronavirus Disease 2019 (COVID-19)data transparency
COVID-19 (Disease)
Adaptive Clinical Trials as Topic
Clinical Decision-Making--ethics
COVID-19
Preprints as Topic
Therapeutics--standards
Identifier to cite or link to this item
http://hdl.handle.net/10713/13597ae974a485f413a2113503eed53cd6c53
10.1136/bmj.m3260